60 Degrees Pharmaceuticals Inc (SXTP) Actualités

Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention

WASHINGTON, Dec. 23, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60...

60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women’s Hospital

The trial (NCT06207370) evaluates tafenoquine combined with standard treatment for babesiosis, addressing a...

60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results

Q3 2024 sales revenue increased 164% year-over-year to $135 thousand.Sequential (quarter-over-quarter) net...

60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. Launch

Highlights include increased ARAKODA® (tafenoquine) brand awareness and utilization through virtual sales...

60 Degrees Pharmaceuticals, Inc. Announces Closing of $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

WASHINGTON, Sept. 06, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60P”...

60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

WASHINGTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60P”...

Form 8-K - Current report

60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements

WASHINGTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60P”...

Form 8-K - Current report

60 Degrees Pharmaceuticals Announces Second Quarter 2024 Results

Q2 2024 net product revenues doubled year-over-year to $125 thousandSequential (quarter-over-quarter) net...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb Study

University of Kentucky will commence a Phase IIb clinical study of drug development candidate SJ733 for...

60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock Split

WASHINGTON, Aug. 06, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the...

Form 424B5 - Prospectus [Rule 424(b)(5)]